Show simple item record

dc.contributor.authorMartín Arias, Luis Hermenegildo 
dc.contributor.authorTreceño, C.
dc.contributor.authorGarcía Ortega, María Pilar 
dc.contributor.authorRodríguez Paredes, Juan
dc.contributor.authorEscudero, Antonio
dc.contributor.authorSáinz Gil, María 
dc.contributor.authorSalado Valdivieso, María Inés
dc.contributor.authorVelasco González, Verónica 
dc.contributor.authorCarvajal García-Pando, Alfonso
dc.date.accessioned2015-03-04T08:56:22Z
dc.date.available2015-03-04T08:56:22Z
dc.date.issued2013
dc.identifier.citationEuropean journal of clinical pharmacology, 2013, vol. 69, no 3, p. 559-564.es
dc.identifier.issn0031-6970es
dc.identifier.urihttp://uvadoc.uva.es/handle/10324/8601
dc.descriptionProducción Científicaes
dc.description.abstractIntroduction Bisphosphonates are used worldwide to treat osteoporosis and, thus, to prevent fractures. Though they have been proven in clinical trials to avoid some fractures, their effectiveness in reducing hip fractures is unclear. The aim of the present study was to explore the relationship between bisphosphonate use and hip fracture trends in Spain. Methods For this purpose, an ecologic study spanning 2002 to 2008 was conducted in Spain. Consumption data were obtained from the Spanish Ministry of Health and Social Policy. The number of hip fractures was obtained from hospital discharges; annual hip fracture rates were determined and standardized using the Spanish 2002 population census. A linear regression was performed between fracture rate and use of bisphosphonates; R2 and Pearson correlation coefficient were calculated. Results From 2002 to 2008, dispensed prescriptions of bisphosphonates in Spain increased from 3.28 to 17.66 DDD/1,000 inhabitants per day. In the same period, the crude hip fracture rate increased from 2.85 to 3.02 cases per 1,000 inhabitants older than 50 years; however, when age standardized rates were estimated, the rate declined from 2.85 to 2.79. Analyzed by sex, the standardized rate for men slightly increased from 1.45 to 1.48, while for women the rate significantly dropped from 4.00 to 3.91.Conclusion A small effect of bisphosphonates on hip fracture rates can not be ruled out; however, other factors might partially explain this decline. Assuming this medication was the only cause for hip fracture rate reduction, the elevated medication cost to avoid a single hip fracture makes it necessary to explore less expensive interventionses
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherSpringer Verlages
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectOsteoporosis - Tratamiento farmacológicoes
dc.titleHip fracture rates and bisphosphonate consumption in Spain. An ecologic studyes
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doi10.1007/s00228-012-1337-zes
dc.identifier.publicationfirstpage559es
dc.identifier.publicationissue3es
dc.identifier.publicationlastpage564es
dc.identifier.publicationtitleEuropean journal of clinical pharmacologyes
dc.identifier.publicationvolume69es
dc.peerreviewedSIes
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record